FIELDS AND PIPELINE Chongqing Precision Biotech Co., Ltd.

We focus on innovative research to develop cell therapy technology in order to defeat malignant tumors. At present, we are mainly engaged in the development and application of gene and cell drugs.

Relying on our original technology, we have mastered key technologies such as immune cell therapy (multi-target CAR-T, universal CAR-T, solid tumor CAR-T, and efficient method for preparing CAR-T cells), stem cell therapy, and gene therapy.

We have deployed more than ten product R&D pipelines for leukemia, lymphoma, myeloma, kidney cancer, colorectal cancer, lung cancer and breast cancer. We obtained 3 Class I biological CAR-T new drugs and 6 indications of implied license.

Product Candidates

Indications

IIT/IIS

Pre-Clinical

Phase I

Phase II

NDA

pCAR-19B

ALL（3-21 pediatric）

ALL（22-70 adult）

C-4-29

Multiple myeloma for adults

Renal cell carcinoma for adults

C-13-60

Colorectal cancer/Gastric cancer/Esophageal cancer

C-13-90

Pancreatic cancer/Lung cancer/Breast cancer

MC-1-50

ALL/NHL

UCAR-T

ALL/NHL

UCAR-NK

AML

Product Candidates	Indications	Approved Time	Product Features
pCAR-19B	ALL（3-21 pediatric）	2019.02	Filling the domestic gap: for the treatment of children and adolescents with relapsed/refractory B-cell acute lymphoblastic leukemia, the self-developed pCAR-19B autologous cell reinfusion preparation is the first CAR-T product in China to enter the phase II clinical stage for this indication. The overall response rate was 100%.
	ALL（22-70 adult）	2020.05
	Lymphoma	2020.05
C-4-29	Multiple myeloma for adults	2020.12	The first target in China: C-4-29 cell preparation with dual indications for both hematological tumors and solid tumors. It is the first CAR-T product targeting renal cell carcinoma solid tumors in China. Both indications have obtained the registered clinical implied license.
C-4-29	Renal cell carcinoma for adults	2021.09
C-13-60	advanced malignant solid tumors that progress or are intolerant after systematic standard treatment and have no effective treatment means	2022.12	The first CAR-T product targeting CEA approved by clinical trials in China.

HOME

ABOUT US

FIELDS AND PIPELINE

PLATFORM AND TECHNOLOGY

BUSINESS AND COOPERATION

MEDIA

JOIN US

CONTACT US